- CA$1.78bn
- CA$735.60m
- $146.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.88 | ||
| PEG Ratio (f) | 0.96 | ||
| EPS Growth (f) | 29.46% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.19 | ||
| Price to Tang. Book | 1.28 | ||
| Price to Free Cashflow | 25.76 | ||
| Price to Sales | 7.11 | ||
| EV to EBITDA | 54.34 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.22% | ||
| Return on Equity | 6.51% | ||
| Operating Margin | -1.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 74.44 | 86.75 | 87.24 | 117.61 | 146.59 | 204.39 | 258.13 | 25.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +5.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cronos Group Inc. is a global cannabinoid company focused on consumer goods products through research and development and innovation. The Company's diverse international brand portfolio includes Spinach, PEACE NATURALS, Lord Jones, LIT, and C.O.G. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, and edibles. Lord Jones is a premium cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer concentrates and edible categories. The Lord Jones brand products are available in the Israeli medical market with cannabis flower products. PEACE NATURALS is a global medical brand engaged in producing cannabis products. LIT is a value‑driven medical cannabis brand, which offers a focused lineup of dried flower products sold in medical markets across Israel, Germany and the United Kingdom.
Directors
- Michael Gorenstein CHM (34)
- Kurt Schmidt PRE (64)
- Robert Madore CFO (56)
- Xiuming Shum EVP (35)
- Shannon Buggy SVP (51)
- Anna Shlimak SVP (35)
- Summer Frein GMG (37)
- Jeffrey Jacobson GMG (35)
- James Rudyk LED (54)
- Jason Adler IND (49)
- Kendrick Ashton IND (45)
- Jody Begley IND (49)
- Murray Garnick IND (61)
- Heather Newman IND (44)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 9th, 2020
- Public Since
- May 7th, 2014
- No. of Employees
- 610
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 368,542,537
- Address
- 4491 Concession Rd 12, TORONTO, L0M 1S0
- Web
- https://thecronosgroup.com/
- Phone
- +1 4165040004
- Auditors
- Davidson & Company LLP
Latest News for CRON
Upcoming Events for CRON
Q3 2026 Cronos Group Inc. Earnings Release
Q3 2026 Cronos Group Inc. Earnings Call
Q4 2026 Cronos Group Inc Earnings Release
Similar to CRON
Apotex Health
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
As of Today at 02:08 UTC, shares in Cronos are trading at CA$4.84. This share price information is delayed by 15 minutes.
Shares in Cronos last closed at CA$4.84 and the price had moved by +44.05% over the past 365 days. In terms of relative price strength the Cronos share price has outperformed the Toronto Stock Exchange 300 Composite Index by +20.87% over the past year.
The overall consensus recommendation for Cronos is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCronos does not currently pay a dividend.
Cronos does not currently pay a dividend.
Cronos does not currently pay a dividend.
To buy shares in Cronos you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$4.84, shares in Cronos had a market capitalisation of CA$1.78bn.
Here are the trading details for Cronos:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: CRON
Based on an overall assessment of its quality, value and momentum Cronos is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cronos is CA$6.50. That is 34.36% above the last closing price of CA$4.84.
Analysts covering Cronos currently have a consensus Earnings Per Share (EPS) forecast of $0.15 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cronos. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +25%.
As of the last closing price of CA$4.84, shares in Cronos were trading +22.97% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cronos PE ratio based on its reported earnings over the past 12 months is 21.88. The shares last closed at CA$4.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cronos' management team is headed by:
- Michael Gorenstein - CHM
- Kurt Schmidt - PRE
- Robert Madore - CFO
- Xiuming Shum - EVP
- Shannon Buggy - SVP
- Anna Shlimak - SVP
- Summer Frein - GMG
- Jeffrey Jacobson - GMG
- James Rudyk - LED
- Jason Adler - IND
- Kendrick Ashton - IND
- Jody Begley - IND
- Murray Garnick - IND
- Heather Newman - IND